Serum Metabolite Profiles Are Altered by Erlotinib Treatment and the Integrin α1-Null Genotype but Not by Post-Traumatic Osteoarthritis

Mickiewicz, Beata; Shin, Sung Yong; Pozzi, Ambra; Vogel, Hans J.; Clark, Arthur W.

doi:10.1021/acs.jproteome.5b00719

Cited by 7 publications

(7 citation statements)

References 69 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, glutamine was identified as elevated in α1-Null mice compared to wild type, suggestive of protective properties, preventing reactive oxygen species induced apoptosis of chondrocytes. 23 A decrease in serotonin was also reported, relating to tryptophan metabolism, which has been associated with OA progression in previous studies, such as in Maerz et al. 22 …”

Section: Resultsmentioning

confidence: 81%

“…In another study, Mickiewicz et al. 23 analysed serum from 200 mice to quantify the effect of Erlotinib (tyrosine kinase inhibitor) treatment and the Integrin α1-Null Genotype on the serum metabolome of mice with surgically induced OA. Integrin α1 heterodimerizes with the beta 1 subunit to form a cell-surface receptor for collagen and laminin.…”

Section: Resultsmentioning

confidence: 99%

“…The number of NMR metabolomic studies of biofluids in OA has greatly increased since 2015 as the field has expanded and progressed rapidly with improved technologies and the increasing application of metabolomics. Authors of significant contribution include the Mickiewicz 4 , 23 , 30 and Peffers 13 , 27 , 33 groups. Many studies noted significant changes consistently in amino acids, pyruvate and creatine, with studies across all biofluids identifying a change in energy utilization, through the increased involvement of lipid metabolism, while also identifying inflammatory processes.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Nuclear magnetic resonance spectroscopy of biofluids for osteoarthritis

Clarke

Anderson

Peffers

2020

British Medical Bulletin

View full text Add to dashboard Cite

Background Osteoarthritis is a common degenerative musculoskeletal disease of synovial joints. It is characterized by a metabolic imbalance resulting in articular cartilage degradation, reduced elastoviscosity of synovial fluid and an altered chondrocyte phenotype. This is often associated with reduced mobility, pain and poor quality of life. Subsequently, with an ageing world population, osteoarthritis is of increasing concern to public health. Nuclear magnetic resonance (NMR) spectroscopy can be applied to characterize the metabolomes of biofluids, determining changes associated with osteoarthritis pathology, identifying potential biomarkers of disease and alterations to metabolic pathways. Sources of data A comprehensive search of PubMed and Web of Science databases using combinations of the following keywords: ‘NMR Spectroscopy’, ‘Blood’, ‘Plasma’, ‘Serum’, ‘Urine’, ‘Synovial Fluid’ and ‘Osteoarthritis’ for articles published from 2000 to 2020. Areas of agreement The number of urine metabolomics studies using NMR spectroscopy to investigate osteoarthritis is low, whereas the use of synovial fluid is significantly higher. Several differential metabolites have previously been identified and mapped to metabolic pathways involved in osteoarthritis pathophysiology. Areas of controversy Conclusions are sometimes conservative or overinflated, which may reflect the variation in reporting standards. NMR metabolic experimental design may require further consideration, as do the animal models used for such studies. Growing points There are various aspects which require improvement within the field. These include stricter adherence to the Metabolomics Standards Initiative, inclusive of the standardization of metabolite identifications; increased utilization of integrating NMR metabolomics with other ‘omic’ disciplines; and increased deposition of raw experimental files into open access online repositories, allowing greater transparency and enabling additional future analyses. Areas timely for developing research Overall, this research area could be improved by the inclusion of more heterogeneous cohorts, reflecting varying osteoarthritis phenotypes, and larger group sizes ensuring studies are not underpowered. To correlate local and systemic environments, the use of blood for diagnostic purposes, over the collection of synovial fluid, requires increased attention. This will ultimately enable biomarkers of disease to be determined that may provide an earlier diagnosis, or provide potential therapeutic targets for osteoarthritis, ultimately improving patient prognosis.

show abstract

Section: Resultsmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nuclear magnetic resonance spectroscopy of biofluids for osteoarthritis

Clarke

Anderson

Peffers

2020

British Medical Bulletin

View full text Add to dashboard Cite

show abstract

“…The majority of studies (n = 11) used the mouse as an animal model to evaluate the development of OA [30][31][32][33][34][35][36][37][38][39][40].…”

Section: Micementioning

confidence: 99%

“…Several models are used for mimicking OA in mice: spontaneous models of OA, which include naturally occurring OA [33,39] and use of genetic modifications [30,35,38]; surgically induced models of OA through technical meniscectomy (MMT) or destabilization of the medial meniscus (DMM) [30,32,36,37,40]; metabolically induced models of OA by high-caloric diets [31,34].…”

Section: Micementioning

confidence: 99%

Sex Specific Determinants in Osteoarthritis: A Systematic Review of Preclinical Studies

Contartese

Tschon

Mattei

et al. 2020

IJMS

View full text Add to dashboard Cite

Osteoarthritis (OA) is a highly prevalent joint disease that primarily affects about 10% of the world’s population over 60 years old. The purpose of this study is to systematically review the preclinical studies regarding sex differences in OA, with particular attention to the molecular aspect and gene expression, but also to the histopathological aspects. Three databases (PubMed, Scopus, and Web of Knowledge) were screened for eligible studies. In vitro and in vivo papers written in English, published in the last 11 years (2009–2020) were eligible. Participants were preclinical studies, including cell cultures and animal models of OA, evaluating sex differences. Independent extraction of articles and quality assessments were performed by two authors using predefined data fields and specific tools (Animals in Research Reporting In Vivo Experiments (ARRIVE) guideline and Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) tool). Twenty-three studies were included in the review: 4 in vitro studies, 18 in vivo studies, and 1 both in vitro and in vivo study. From in vitro works, sex differences were found in the gene expression of inflammatory molecules, hormonal receptors, and in responsiveness to hormonal stimulation. In vivo research showed a great heterogeneity of animal models mainly focused on the histopathological aspects rather than on the analysis of sex-related molecular mechanisms. This review highlights that many gaps in knowledge still exist; improvementsin the selection and reporting of animal models, the use of advanced in vitro models, and multiomics analyses might contribute to developing a personalized gender-based medicine.

show abstract